Be a Smart Investor: September 2019

Monday, September 30, 2019

Today's Top 6 Gainers In Healthcare Sector (DOVA, CAPR, SMMT.)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2oFV8pJ
via IFTTT

Futures Pointing To Modestly Higher Open On Wall Street

The major U.S. index futures are currently pointing to a modestly higher opening on Monday, with stocks likely to move back to the upside following the weakness seen last Friday.

from RTT - Market Analysis https://ift.tt/2n4FBzq
via IFTTT

Cal-Maine Foods Q1 Results Miss Estimates - Quick Facts

Cal-Maine Foods, Inc. (CALM) reported Monday a net loss of $45.72 million or $0.94 per share for the first quarter, compared to net income of $12.41 million or $0.26 per share in the year-ago quarter.

from RTT - Earnings https://ift.tt/2oz80hw
via IFTTT

FDA Approves First Drug To Treat Pediatric GPA And MPA

Vasculitis, which refers to inflammation of the blood vessels, is an autoimmune disease wherein the immune system attacks the body's own cells for unknown reasons. There are approximately 20 different disorders that are classified as "vasculitis". (Source: Johns Hopkins Vasculitis Center).

from RTT - Biotech https://ift.tt/2mZ6k0i
via IFTTT

Healthcare IPOs For The Week Ahead

The IPO activity in the U.S. pharma/biotech sector has had a strong showing so far this year, with 46 listings in the 9-month period of the year and 12 listings in the third quarter.

from RTT - Biotech https://ift.tt/2oj6OPb
via IFTTT

Biotech Stocks Facing FDA Decision In October 2019

It has been an eventful September, with a number of notable firsts achieved on the regulatory front. Now, let's take a look at the companies that await a ruling from the FDA in October 2019.

from RTT - Biotech https://ift.tt/2miQPQE
via IFTTT

Trade Talk Optimism May Generate Early Buying Interest

The major U.S. index futures are currently pointing to a higher opening on Friday, with stocks likely to extend the recovery from yesterday's early weakness.

from RTT - Market Analysis https://ift.tt/2m8vj0U
via IFTTT

Daily Mail owner leads race to buy the i newspaper

DMGT is frontrunner in pack of publishers after being asked into exclusive talks by owners

The owner of the Daily Mail has emerged as the frontrunner to buy the i newspaper after being asked to enter exclusive talks by the i’s parent, JPI Media.

Daily Mail & General Trust is involved in an auction of assets put up for sale by JPI Media, formerly known as Johnston Press, which publishes more than 200 regional titles including The Scotsman and Yorkshire Post.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2n9CwxG

Actuant Guides FY20 Below Estimates - Quick Facts

While reporting financial results for the fourth quarter and fiscal 2019 on Thursday, Actuant Corp. (ATU) initiated adjusted earnings and sales outlook for the full-year 2020. The company also provided guidance for the first quarter of fiscal 2020.

from RTT - Earnings https://ift.tt/2ntvYdn
via IFTTT

Conagra Brands Reiterates FY20 Outlook - Quick Facts

While reporting its financial results for the first quarter on Thursday, Conagra Brands, Inc. (CAG) reiterated its financial outlook for the full-year 2020.

from RTT - Earnings https://ift.tt/2m1lLVh
via IFTTT

Rite Aid Narrows FY20 Adj. EPS Outlook Range - Quick Facts

While reporting financial results for the second quarter on Thursday, drugstore chain Rite Aid Corp. (RAD) narrowed its earnings outlook for the full-year 2020, while maintaining annual revenue and same store sales guidance.

from RTT - Earnings https://ift.tt/2mVFENK
via IFTTT

FactSet Guides FY20 Below Estimates - Quick Facts

While reporting financial results for the fourth quarter and fiscal 2019 on Thursday, FactSet (FDS) initiated earnings and revenue outlook for the full-year 2020.

from RTT - Earnings https://ift.tt/2lKG8pH
via IFTTT

Accenture Guides FY20 EPS Below Estimates; Boosts Dividend 10% - Quick Facts

While reporting financial results for the fourth quarter and fiscal 2019 on Thursday, Accenture Plc (ACN) initiated earnings and revenue growth outlook for the full-year 2020.

from RTT - Earnings https://ift.tt/2lioARl
via IFTTT

Jazz Pharma Presents JZP-258 Phase 3 Study Data At World Sleep 2019

Jazz Pharmaceuticals plc (JAZZ) presented positive data from its Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy. The results from the trial were reported by the company on March 26, 2019.

from RTT - Biotech https://ift.tt/2mUrCfi
via IFTTT

Ancora Heart 's AccuCinch Therapy Shows Positive Results In Interim Study

Ancora Heart Inc., a privately-held medical device company, on Wednesday said that its investigational non-surgical heart failure therapy AccuCinch Ventricular Repair System for the treatment of systolic heart failure showed positive results in its study dubbed CorCinch FMR.

from RTT - Biotech https://ift.tt/2nsXub5
via IFTTT

Enanta's Phase 2a Study Of EDP-305 In NASH Hits Goals

Enanta Pharmaceuticals, Inc. (ENTA) on Wednesday said its Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH), dubbed ARGON-1, achieved its primary and secondary endpoints.

from RTT - Biotech https://ift.tt/2mSDQEU
via IFTTT

5 Top Gainers In Healthcare Sector Today (OVID, PHAS, TXMD.)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2lhsWZa
via IFTTT

Abbott's Newly Approved Blood Test Could Help Identify Heart Attacks Sooner

Abbott Laboratories (ABT) said Wednesday that the U.S. Food and Drug Administration approved its Architect Stat High Sensitivity Troponin-I blood test that could help detect heart attacks faster and more accurately than the standard troponin tests.

from RTT - Biotech https://ift.tt/2l8rYOQ
via IFTTT

Political Uncertainty May Weigh On Wall Street

The major U.S. index futures are pointing to a slightly lower opening on Wednesday following the downturn seen over the course of the previous session.

from RTT - Market Analysis https://ift.tt/2ncg5rL
via IFTTT

China Ceramics H1 Loss Widens - Quick Facts

Chinese ceramic tiles maker China Ceramics Co., Ltd. (CCCL) reported Wednesday that net loss for the first half of 2019 ended June 30, 2019 widened to RMB 193.1 million or $28.5 million from RMB 71.9 million or $11.3 million in the same period of 2018. Loss per share was RMB 32.23 or $4.75, compared to loss per share of RMB 17.23 or $2.71 last year.

from RTT - Earnings https://ift.tt/2l71ltA
via IFTTT

Today's Top 5 Losers In Healthcare Sector (ECOR, NTEC, AIM...)

The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

from RTT - Biotech https://ift.tt/2lvxRFK
via IFTTT

Futures Pointing To Initial Strength On Wall Street

The major U.S. index futures are pointing to a higher opening on Tuesday following the lackluster performance seen in the previous session.

from RTT - Market Analysis https://ift.tt/2laul3L
via IFTTT

Jabil Guides Q1 In Line With Estimates - Quick Facts

While reporting preliminary, unaudited financial results for its fourth quarter and fiscal year 20219 on Tuesday, Jabil, Inc. (JBL) provided earnings and revenue guidance for the first quarter in line with analysts' estimates.

from RTT - Earnings https://ift.tt/2l9W3xz
via IFTTT

Bristol-Myers Squibb Says CHMP Recommends Approval Of Opdivo - Quick Facts

Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) announced Tuesday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused over 60 minutes every four weeks (Q4W).

from RTT - Biotech https://ift.tt/2l9zOI4
via IFTTT

BlackBerry Trims FY20 Adj. Revenue Growth Outlook - Quick Facts

While reporting financial results for the second quarter on Tuesday, Canadian technology company BlackBerry Ltd. (BB, BB.TO) trimmed its adjusted revenue growth guidance for the full-year 2020.

from RTT - Earnings https://ift.tt/2mqrRhz
via IFTTT

6 Top Gainers In Healthcare Sector (AVDL, KOOL, MLNT.)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2melQ7M
via IFTTT

Global Economic Worries May Weigh On Wall Street

The major U.S. index futures are currently pointing to a lower opening on Monday, with stocks likely to extend the downward move seen last Friday.

from RTT - Market Analysis https://ift.tt/2m55A92
via IFTTT

What Awaits DURECT In Q4?

DURECT's resubmitted NDA for POSIMIR is under FDA review - with a decision expected by December 27, 2019. DUR-928 in IV form showed positive results in a Phase 2a trial and additional data is expected at the upcoming AASLD Liver Meeting in Boston in November. Given the fact that the company has upcoming clinical trial and regulatory catalysts, this stock is worth keeping an eye on.

from RTT - Biotech https://ift.tt/34YUeFL
via IFTTT

Are You Aware Of Restless Legs Syndrome Awareness Day?

Every year, September 23, is observed as RLS Awareness Day to educate the public about this neurologic and sleep-related movement disorder. The first Restless Legs Syndrome Awareness Day was observed on September 23, 2012.

from RTT - Biotech https://ift.tt/30JKOu6
via IFTTT

Week Ahead In Pharma: 9 Stocks To Watch (AVXL, GMAB, ARAV.)

Sienna Biopharmaceuticals Inc. (SNNA) ended the week as the worst performer in the healthcare sector - with its shares down 77 percent. Now, here are some of the pharma/biotech stocks to watch out for in the week starting September 24.

from RTT - Biotech https://ift.tt/32ZrFWT
via IFTTT

Optimism About Stimulus, Trade Talks May Lead To Higher Open

The major U.S. index futures are currently pointing to a modestly higher opening on Friday after the major averages closed mixed for two straight sessions.

from RTT - Market Analysis https://ift.tt/2IfTeTA
via IFTTT

FDA Approves Merck's SNDAs For PIFELTRO And DELSTRIGO - Quick Facts

Merck (MRK), known as MSD outside the U.S. and Canada, announced Friday that the U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications (sNDAs) for PIFELTRO (in combination with other antiretroviral agents) and DELSTRIGO (as a complete regimen) that expand their indications to include adult patients with HIV-1 infection.

from RTT - Biotech https://ift.tt/2Ax7SBZ
via IFTTT

This Day That Year: Elanco Animal Health

Shares of Elanco Animal Health Inc. (ELAN) are down nearly 28 percent from a high of $37.61 recorded on September 27, 2018.

from RTT - Biotech https://ift.tt/2AtSc2j
via IFTTT

5 Top Losers In Healthcare Sector (NSPR, NTEC, ACRS.)

The following are some of the healthcare stocks that posted the biggest percentage decline on Thursday.

from RTT - Biotech https://ift.tt/2V33jZu
via IFTTT

6 Top Gainers In Healthcare Sector (AIM, EDSA, ARAV.)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2Oe98BJ
via IFTTT

Uncertainty About Interest Rate Outlook May Lead To Choppy Trading

The major U.S. index futures are pointing to a roughly flat opening on Thursday, with stocks likely to extend the choppy trading seen late in the previous session.

from RTT - Market Analysis https://ift.tt/2M4Tiqm
via IFTTT

JD Sports' buyout of rival could be bad deal for shoppers, says CMA

Watchdog says it will carry out investigation if concerns over £90m deal are not addressed

The UK’s competition watchdog has said JD Sports’ £90m deal to buy its smaller rival Footasylum could result in higher prices and that it will carry out an investigation unless JD can address its concerns.

The Competition and Markets Authority (CMA) said its initial investigation found the deal could result in a “substantial lessening of competition”.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2LE7VCk

Darden Reaffirms FY20 Outlook; Announces $500 Mln Share Buyback, Qtly Dividend

While reporting financial results for the first quarter on Thursday, Darden Restaurants, Inc. (DRI) reaffirmed its financial outlook for the full-year 2020, which is a 53-week fiscal year. The outlook includes the impact of the additional week.

from RTT - Earnings https://ift.tt/2LZyVet
via IFTTT

Wave Life Raring To Go The Distance

Shares of Wave Life Sciences Ltd. (WVE) are down over 55% from their 52-week high of $56 recorded on September 24, 2018.

from RTT - Biotech https://ift.tt/30a5lNk
via IFTTT

5 Top Losers In Healthcare Sector (ZYNE, PTCT, MRNS.)

The following are some of the healthcare stocks that posted the biggest percentage decline on Wednesday.

from RTT - Biotech https://ift.tt/31ytBFx
via IFTTT

5 Top Gainers In Healthcare Sector (LXRX, ECOR, ARAV.)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2Nmfr6L
via IFTTT

FDA, Canada, Australia Collaborate On Cancer Drugs Review

The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world.

from RTT - Biotech https://ift.tt/2LCEMY2
via IFTTT

Fed Decision Remains In Focus On Wall Street

The major U.S. index futures are pointing to a slightly lower opening on Wednesday, with stocks likely to give back ground after ending the previous session modestly higher.

from RTT - Market Analysis https://ift.tt/2LDBMux
via IFTTT

General Mills Q1 Profit Tops Estimates, Organic Sales Down 1% - Quick Facts

General Mills (GIS) said its profit and earnings growth were ahead of its expectations for the first-quarter. Net sales decreased 2 percent, while organic net sales were down 1 percent, for the quarter. The decline in organic net sales was due to lower organic volume, partially offset by positive organic net price realization and mix across all operating segments. Looking forward, the company reaffirmed its fiscal 2020 outlook. Shares of General Mills were down more than 4 percent in pre-market trade on Wednesday.

from RTT - Earnings https://ift.tt/2I8ZPiM
via IFTTT

FDA Makes 1st Approval Under Project Orbis, KDMN On Watch, TBIO Down After-hrs

Today's Daily Dose brings you news about Bankruptcy filing of Sienna Biopharma; the first approval under FDA's Project Orbis, and public offering of Translate Bio.

from RTT - Biotech https://ift.tt/2O81skL
via IFTTT

Kingfisher H1 Adj. Pre-tax Profit Rises; LFL Sales Down 1.8% - Quick Facts

Kingfisher plc (KGF.L) reported that its adjusted pre-tax profit was up 3.7 percent for the 6 months ended 31 July 2019, reflecting lower transformation P&L costs. Like-for-like sales were down 1.8 percent with growth in Screwfix, Poland and Romania offset by B&Q and France. Looking forward, Kingfisher said the outlook across its main markets for the rest of the year remains mixed, with the UK facing ongoing uncertainty. For fiscal 19/20, gross margin percentage guidance is unchanged. Kingfisher also announced that Thierry Garnier will join as CEO on 25 September.

from RTT - Earnings https://ift.tt/2NilBVv
via IFTTT

5 Top Losers In Healthcare Sector (ONTX, LPTX, SLRX.)

The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

from RTT - Biotech https://ift.tt/2Vbp7Cp
via IFTTT

6 Top Gainers In Healthcare Sector (ACRS, NSPR, AVDL.)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2LYZbp9
via IFTTT

Cracker Barrel Guides FY20 Above Estimates - Quick Facts

While reporting financial results for the fourth quarter of fiscal 2019 on Tuesday, Cracker Barrel Old Country Store, Inc. (CBRL) initiated earnings and revenue guidance for the full-year 2020, above analysts' estimates.

from RTT - Earnings https://ift.tt/2LAQZwm
via IFTTT

Futures Pointing To Initial Weakness On Wall Street

The major U.S. index futures are pointing to a lower opening on Tuesday, with stocks likely to add to the losses posted in the previous session.

from RTT - Market Analysis https://ift.tt/32RvT2J
via IFTTT

Apogee Enterprises Reaffirms FY20 Adj. EPS Outlook - Quick Facts

While reporting financial results for the first quarter of fiscal 2020 on Tuesday, Apogee Enterprises, Inc. (APOG) reaffirmed earnings and revenue growth guidance for the full-year 2020.

from RTT - Earnings https://ift.tt/2M9qtcL
via IFTTT

XLRN Pulls The Plug On FSHD Study, KPTI Well Funded, ACRS Up On Wart Trial Data

Today's Daily Dose brings you news about Acceleron Pharma pulling the plug on facioscapulohumeral muscular dystrophy trial; Aclaris Therapeutics' THWART-2 trial results; the $150 million investment by HealthCare Royalty Partners in Karyopharm and the upcoming regulatory catalyst of Seattle Genetics.

from RTT - Biotech https://ift.tt/2UY93nl
via IFTTT

Acceleron Pharma's ACE-083 Fails In Phase 2 Study For FSHD

Acceleron Pharma Inc. (XLRN) on Monday said its investigational therapy ACE-083 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.

from RTT - Biotech https://ift.tt/32KCxYl
via IFTTT

AVITA Gets FDA IDE Approval Of Soft Tissue Reconstruction Pivotal Clinical Trial

AVITA Medical (AVMXY.OB) on Monday announced that the FDA has approved the company's Investigational Device Exemption (IDE) application to conduct a study of the Autologous Cell Harvesting Device RECELL in combination with meshed autografting for the treatment of acute soft tissue injuries, defects, and reconstruction.

from RTT - Biotech https://ift.tt/32KH64R
via IFTTT

5 Top Losers In Healthcare Sector (CHFS, ONTX, DRAD.)

The following are some of the healthcare stocks that posted the biggest percentage decline on Monday.

from RTT - Biotech https://ift.tt/306nn1W
via IFTTT

7 Top Gainers In Healthcare Sector (KOD, LXRX, WVE...)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/31roFly
via IFTTT

Jump In Crude Oil Prices May Weigh On Wall Street

The major U.S. index futures are currently pointing to a lower opening on Monday following the notable upward move seen last week.

from RTT - Market Analysis https://ift.tt/2Al2C3Z
via IFTTT

Kodiak Sciences Presents Promising KSI-301 Durability Data

The emerging durability data were from the cohort of treatment-naïve wet AMD patients, and all the patients achieved a treatment-free interval of three months or longer, with the majority reaching a four- or five-month interval and continuing to be followed without retreatment to date.

from RTT - Biotech https://ift.tt/2Nhs0QV
via IFTTT

Thomas Cook in race to secure £1.1bn rescue deal

Travel firm wants delay to bondholders’ meeting as it tries to stave off financial collapse

The beleaguered travel firm Thomas Cook will on Monday request a delay to a key bondholders’ meeting on Wednesday to try to maximise the chances of securing a £1.1bn emergency rescue package to help stave off imminent financial collapse.

The company is involved in 11th-hour talks as it seeks to finalise the terms of the proposed restructuring agreement with the Chinese conglomerate Fosun, its lenders and bondholders.

Thomas Cook owes its name to a humble and deeply religious 32-year-old cabinet-maker who, one June morning in 1841, hiked the 15 miles from his home in Market Harborough to Leicester, to attend a temperance meeting.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/305pV1m

Healthcare IPOs For The Week Ahead

Mountain View, California-based IGM Biosciences is a biotechnology company developing engineered IgM antibodies for the treatment of cancer patients. Immunoglobulin M (IgM) is a class of antibody naturally produced by the human immune system.

from RTT - Biotech https://ift.tt/2Lyddz6
via IFTTT

UK blackouts raise questions over private sector’s right to profit from power

Energy network companies are under scrutiny after last month’s outage, the worst of its kind in a decade

There is never a good time for a blackout, but for Britain’s energy companies the timing of last month’s power failure could scarcely have been worse.

The best that the owners of the UK’s energy pipes and wires can expect in the coming years is a tighter squeeze on their deflated profits by the industry regulator. A Labour government could support nationalisation. In the meantime, investors are turning their backs on energy network companies.

Why did multiple failures cascade through the system following a single lightning strike?

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/32J1rHO

Week Ahead In Pharmaceuticals: 7 Stocks To Watch (AIMT, LXRX, TXG.)

The week ending September 14, 2019, witnessed a string of disappointments on the Alzheimer's drug development front. Now, here are some of the pharma/biotech stocks to watch out for in the week starting September 15.

from RTT - Biotech https://ift.tt/31m04OZ
via IFTTT

Optimism About Trade Deal May Lead To Continued Strength On Wall Street

The major U.S. index futures are currently pointing to a higher opening on Friday, with traders expressing renewed optimism about a possible U.S.-China trade deal.

from RTT - Market Analysis https://ift.tt/2ZUVk6m
via IFTTT

5 Top Losers In Healthcare Sector (TOCA, ADVM, CPRX.)

The following are some of the healthcare stocks that posted the biggest percentage decline on Thursday.

from RTT - Biotech https://ift.tt/2LsSIDO
via IFTTT

5 Top Gainers In Healthcare Sector (SINT, JAGX, EVLO.)

The following are some of today's top gainers in the pharma/biotech sector.

from RTT - Biotech https://ift.tt/2O9gGpJ
via IFTTT

ECB Stimulus, Tariff Delay May Generate Early Buying Interest

The major U.S. index futures are pointing to a higher opening on Thursday, with stocks likely to extend the strong upward move seen over the course of the previous session.

from RTT - Market Analysis https://ift.tt/2LPVbHq
via IFTTT

What Awaits Aimmune Therapeutics Tomorrow?

The FDA's Allergenic Products Advisory Committee, or APAC, is slated to determine whether or not to recommend approval of Palforzia, an experimental peanut allergy drug, developed by Aimmune Therapeutics Inc. (AIMT), on September 13, 2019.

from RTT - Biotech https://ift.tt/2Q4VPX6
via IFTTT

Chinese Tariff Exemptions May Generate Early Buying Interest

The major U.S. index futures are pointing to a higher opening on Wednesday following the lackluster performance seen over the past few sessions.

from RTT - Market Analysis https://ift.tt/306Y9MT
via IFTTT

This Week's Healthcare IPOs

The end of the third quarter is fast approaching. The third quarter IPO activity in the U.S. pharma/biotech sector has been somewhat tepid with around 9 listings so far in the quarter.

from RTT - Biotech https://ift.tt/2NUnJSX
via IFTTT

5 Top Losers In Healthcare Sector (EMMA, MBOT, XERS.)

The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

from RTT - Biotech https://ift.tt/34BtEC5
via IFTTT

5 Top Gainers In Healthcare Sector (MNK, ENDP, MLNT...)

The following are some of today's top gainers in the healthcare sector.

from RTT - Biotech https://ift.tt/34AWin1
via IFTTT

Futures Pointing To Another Lackluster Session On Wall Street

The major U.S. index futures are pointing to a roughly flat opening on Tuesday, with stocks likely to extend the lackluster performance seen over the two previous sessions.

from RTT - Market Analysis https://ift.tt/2A2GAmG
via IFTTT

Christopher & Banks Backs FY19 Sales Outlook - Quick Facts

Specialty women's apparel retailer Christopher & Banks Corp. (CBKC) reported Tuesday that comparable sales for the second quarter declined 4.1 percent following a 0.8 percent increase in the same period last year. Comparable sales for the third quarter to-date are also running positive in mid-single digits.

from RTT - Earnings https://ift.tt/2Q23yoP
via IFTTT

InMode In Steady Mode...

InMode Ltd. (INMD), which is developing devices that use minimally invasive radio-frequency technology for aesthetic medical procedures, has been hitting new highs.

from RTT - Biotech https://ift.tt/301Z80H
via IFTTT

5 Top Losers In Healthcare Sector (NTRP, AKRO, SAVA...)

The following are some of the healthcare stocks that posted the biggest percentage decline on Monday.

from RTT - Biotech https://ift.tt/2Q2vnxm
via IFTTT

6 Top Gainers In Healthcare Sector (ACAD, ARDX, KOOL.)

The following are some of today's top gainers in the healthcare sector.

from RTT - Biotech https://ift.tt/2LoPzVF
via IFTTT

Optimism About Further Stimulus May Generate Buying Interest

The major U.S. index futures are currently pointing to a higher opening on Monday, with stocks likely to add to the strong gains posted last week.

from RTT - Market Analysis https://ift.tt/2ZPIUMb
via IFTTT

Futures Remain Positive Despite Weaker Than Expected Jobs Data

The major U.S. index futures are currently pointing to a higher opening on Friday, with stocks likely to extend the strong upward move seen over the two previous sessions.

from RTT - Market Analysis https://ift.tt/2UAU4j6
via IFTTT

Genesco Q2 Comps Up 3%; Boosts FY20 Adj. EPS Outlook - Quick Facts

Specialty retailer Genesco, Inc. (GCO) announced Friday that comparable sales increased 3 percent, with stores up 1 percent and direct up 20 percent, for the second quarter.

from RTT - Earnings https://ift.tt/2ZAKMZS
via IFTTT

Brady Corp. Guides FY20 EPS In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter on Friday, Brady Corp. (BRC) initiated its earnings guidance for the full-year 2020.

from RTT - Earnings https://ift.tt/2HRtltn
via IFTTT

Interesting Stocks To Watch On Sept. 6 (SAIC, ZM, DOCU, LULU)

What makes these stocks interesting? Science Applications International Corp. (SAIC) Zoom Video Communications Inc. (ZM) DocuSign (DOCU) lululemon athletica inc. (LULU)

from RTT - Before the Bell https://ift.tt/2MY7FQh
via IFTTT

Trade Talks News, Upbeat Jobs Data May Generate Buying Interest

John Wiley & Sons Cuts FY20 Adj. EPS Outlook - Quick Facts

While reporting financial results for the first quarter of fiscal 2020 on Thursday, research and education company John Wiley & Sons, Inc. (JW-A, JW-B) lowered its adjusted earnings guidance for the full-year 2020, while raising annual revenue outlook.

from RTT - Earnings https://ift.tt/2zXUYfG
via IFTTT

G-III Apparel Cuts FY20 Earnings Outlook - Quick Facts

While reporting financial results for the second quarter on Thursday, G-III Apparel Group, Ltd. (GIII) lowered its earnings guidance for the full-year 2020, while raising annual sales outlook.

from RTT - Earnings https://ift.tt/2ZNX4to
via IFTTT

5 Top Gainers In Healthcare Sector (OPGN, MRNS, ONTX.)

The following are some of today's top gainers in the healthcare sector.

from RTT - Biotech https://ift.tt/2MWgwSJ
via IFTTT

Positive Developments Overseas May Lead To Initial Strength On Wall Street

The major U.S. index futures are currently pointing to a higher opening on Wednesday, with stocks likely to move back to the upside following the sharp pullback in the previous session.

from RTT - Market Analysis https://ift.tt/2MTKgQa
via IFTTT

American Eagle Guides Q3 Adj. EPS Below View - Quick Facts

While reporting financial results for the second quarter on Wednesday, specialty retailer American Eagle Outfitters, Inc. (AEO) provided earnings and comparable sales growth guidance for the third quarter.

from RTT - Earnings https://ift.tt/2HHD3hW
via IFTTT

Two Down, Two To Go For Ardelyx

Shares of Ardelyx Inc. (ARDX) closed at a new 52-week high of $5.82 yesterday, a gain of over 70% in one day, thanks to the second positive hyperphosphatemia study, dubbed AMPLIFY.

from RTT - Biotech https://ift.tt/2LlrXQA
via IFTTT

5 Top Gainers In Healthcare Sector (ARDX, CDTX, EBS...)

The following are some of today's top gainers in the healthcare sector.

from RTT - Biotech https://ift.tt/310s9LS
via IFTTT

If ministers want to rebalance the economy, they must scrap HS2 | Larry Elliott

Improving rail links in the north is a far better use of £80bn-plus than continuing with a delayed project

The future of HS2, Britain’s most ambitious infrastructure project, is hanging by a thread after the transport secretary, Grant Shapps, announced a delay of up to five years to complete its first phase, accompanied by a massive increase in the estimated cost.

For the beleaguered construction sector, the timing could hardly have been worse. Orders for new work have been drying up at a rate not seen for a decade, so the scrapping of such a large infrastructure project would come as a severe blow.

Continue reading...

from Mergers and acquisitions | The Guardian https://ift.tt/2MZUdvx

Lingering Trade War Worries May Weigh On Wall Street

The major U.S. index futures are currently pointing to a lower opening on Tuesday as traders return to their desks following the long holiday weekend.

from RTT - Market Analysis https://ift.tt/2NSTk7D
via IFTTT

Monday, September 30, 2019

Sunday, September 29, 2019

Friday, September 27, 2019

Thursday, September 26, 2019

Wednesday, September 25, 2019

Tuesday, September 24, 2019

Monday, September 23, 2019

Saturday, September 21, 2019

Friday, September 20, 2019

Thursday, September 19, 2019

Wednesday, September 18, 2019

Tuesday, September 17, 2019

Monday, September 16, 2019

Sunday, September 15, 2019

Saturday, September 14, 2019

Friday, September 13, 2019

Thursday, September 12, 2019

Wednesday, September 11, 2019

Tuesday, September 10, 2019

Monday, September 9, 2019

Friday, September 6, 2019

Thursday, September 5, 2019

Wednesday, September 4, 2019

Tuesday, September 3, 2019